Entera Health, Inc. Announces Presentations at Digestive Disease Week 2013

CARY, NC (Business Wire May 14, 2013) – Entera Health, Inc. announces today three presentations will be given at Digestive Disease Week DDW® 2013, which is being held in Orlando, FL, Saturday, May 18 – Tuesday, May 21.

Rome IV Symposium May 17, 2013 Eric Weaver, PhD; “A New Approach to the Clinical Dietary Management of IBS-D” 

Rome Advisory Council May 18, 2013 Bruce Burnett, PhD; “Medical Foods: A History of Chronic Condition and Disease Management”

DDW 2013,  Abstract # 1595784 May 18, 2013, Gerald L. Klein, MD; “Efficacy of Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) in Patients with Diarrhea- Predominant Irritable Bowel Syndrome (IBS-D)”

Dr. Weaver’s presentation to the Rome Foundation will provide initial clinical data on the use of the prescription medical food, EnteraGam™ (serum-derived bovine immunoglobulin/protein isolate; SBI), for diarrhea-predominant irritable bowel syndrome (IBS-D) while Dr. Burnett will focus on education regarding the FDA-regulated category of medical foods. Dr. Klein’s poster presentation at DDW will focus on the use of EnteraGam™ for the clinical dietary management of diarrhea-predominant irritable bowel syndrome (IBS-D).

The Rome Foundation is an independent not for profit 501(c) 3 organization that provides support for activities designed to create scientific data and educational information to assist in the diagnosis and treatment of functional gastrointestinal disorders (FGIDs). Its mission is to improve the lives of people with functional GI disorders.

EnteraGam™ (SBI) is a prescription medical food product composed of immunoglobulins and other proteins which have been shown to manage enteropathy in several clinical studies under medical supervision (for more information, please email eh.medicalinfo@enterahealth.com).

About Entera Health, Inc.
Entera Health, Inc. is a biotherapeutic company focused on improving worldwide health through development of clinically safe biotherapeutics to address unmet needs. Entera conducts continuing research utilizing value added proteins and protein co-products to find additional compounds that positively impact human health. Products are being developed for oncology, gastroenterology, and immune disorders.

Visit our site:  www.enterahealth.com

Tom Heck, VP of Corporate Development; 515-963-7599;  tom.heck@enterahealth.com

Click here to read the full article.